CD Biosynsis provides a specialized platform for HeLa Cells Multi-Gene Knockout (KO) Strain Construction, enabling the simultaneous disruption of multiple genetic loci within the same cell line. HeLa cells, characterized by their complex hyper-triploid genome (often carrying 3 to 6 copies of each chromosome), present a significant challenge for complete gene inactivation. Our service utilizes advanced Multiplex CRISPR-Cas9 strategies and high-efficiency delivery systems (such as RNP electroporation) to ensure that all alleles of every target gene are successfully disrupted. This multi-gene knockout capability is essential for studying gene redundancy, synergistic pathway interactions, and complex metabolic networks in a human cancer context, providing researchers with clean, poly-KO monoclonal cell lines for high-impact functional genomics.
Get a QuoteTraditional single-gene knockouts often fail to reveal full phenotypes due to genetic compensation or redundant pathway components. In HeLa cells, the presence of extra chromosomal copies makes the removal of "wild-type" background even more difficult. Our Multi-Gene Knockout service addresses these hurdles by:
RNP Co-Transfection
Simultaneous delivery of multiple Ribonucleoprotein (RNP) complexes. This DNA-free method reduces off-target effects and maximizes transient cutting efficiency for polyploid targets.
Poly-cistronic gRNA Vectors
Custom vector construction expressing multiple sgRNAs under individual or tRNA-linked promoters, ensuring balanced expression of all targeting components.
Sequential Knockout
For genes where simultaneous KO might impair initial cell recovery, we offer iterative rounds of editing and clonal selection to build up to a triple or quadruple KO strain.
Synthetic Lethality Studies
Determining which gene combinations result in cell death, identifying potential multi-target therapeutic vulnerabilities in cervical cancer models.
Redundant Pathway Mapping
Disrupting parallel signaling nodes (e.g., AKT1 and AKT2) to completely ablate a biological response that would otherwise persist with single-gene KOs.
Viral Host Factor Profiling
Removing multiple host receptors or entry factors (e.g., different heparan sulfate proteoglycans) to study viral entry mechanisms with zero background interference.
Deep Sequencing (NGS)
High-throughput sequencing of all targeted loci to quantify the indel frequency across all alleles, ensuring 100% frameshift achievement in the aneuploid background.
Western Blot Profiling
Protein-level validation to confirm the total loss of multiple target proteins, verifying the functional success of the multi-gene disruption.
1. Multiplex Design
2. RNP/Vector Delivery
3. Monoclonal Screening
4. Poly-Allelic Verification
Analyze the copy number of each target gene in the specific HeLa strain. Design 2 to 3 sgRNAs per gene to maximize the probability of complete allelic knockout.
Select the optimal multiplexing vector or RNP combination to ensure high-efficiency simultaneous cutting.
Perform co-transfection or electroporation of the CRISPR components.
Perform transient selection or FACS enrichment of the transfected population to increase the success rate of multi-locus editing.
NGS Analysis: Sequence all targeted regions across all copies of the genes to confirm no wild-type alleles remain.
Functional Validation: Western blot or functional assays to confirm the complete silencing of the multiple target pathways.
Delivery: Provide the cryopreserved monoclonal multi-KO strain and a full characterization report.
High Allelic Success Rate
Our protocols are optimized for the hyper-triploid HeLa genome, ensuring that every gene copy (up to 6+) is successfully targeted and disrupted.
Reduced Toxicity
Use of RNP technology minimizes cellular stress during the simultaneous knockout of multiple essential or semi-essential pathway genes.
Clean Genetic Background
We provide scarless, antibiotic-free monoclonal lines that prevent confounding effects from secondary integrations or marker overexpression.
Pathway-Scale Engineering
Ability to knockout entire protein complexes or parallel signaling nodes, providing a definitive tool for systems biology research.
1. How many genes can be knocked out simultaneously in HeLa cells?
Typically, we can target 2 to 4 genes in a single multiplexed reaction. For projects requiring 5 or more KOs, we recommend a sequential development strategy to ensure cell viability and monoclonal quality.
2. How do you confirm all copies are knocked out in a triploid/tetraploid cell?
We use Deep Sequencing (NGS) to analyze the ratio of different indel types. A successful multi-allelic KO is confirmed when 100% of the reads show frameshift mutations and zero wild-type sequences are detected across all targeted loci.
3. What if the combination of knockouts is lethal to the cells?
If lethal combinations are suspected, we can offer an Inducible KO system or CRISPRi (interference) to provide tunable or temporary repression, allowing for the study of the phenotype without immediate cell death.
4. What is the typical lead time for a double or triple KO HeLa line?
Due to the increased complexity of screening for multi-locus modifications in an aneuploid line, the typical timeline is 12 to 18 weeks from design to delivery of a verified monoclonal line.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.